Dr. Lekakis on Current Research With CAR T-Cell Therapy

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Bispecific CAR T cells are an area of active investigation in B-cell malignancies, explains Lekakis. Currently, tisagenlecleucel (Kymriah) and axicabtagene-ciloleucel (Yescarta) are approved for patients with relapsed or refractory diffuse large B-cell lymphoma, both of which target CD19. Some of the dual targets under investigation include CD19 and CD22. Dual-targeted CAR T cells may be more effective, explains Lekakis as CAR T-cell evasion can occur with CD19 clones, he explains.

In multiple myeloma, several products are under investigation—–all of which target BCMA. Some companies are combining CAR T cells with PD-1/PD-L1 inhibitors to try to evade T-cell exhaustion, explains Lekakis. Combinations of CD19-specific CAR T cells and lenalidomide (Revlimid) and rituximab (Rituxan) are also under exploration, adds Lekakis.

Related Videos
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
Joseph Fraietta, PhD, on Investigating Molecular Pathways of CAR T-Cell Resistance
© 2023 MJH Life Sciences

All rights reserved.